• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      The Swedish Council on Health Technology Assessment (SBU)
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25471 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2020     Scottish Health Technologies Group (SHTG) Continuous glucose monitoring in pregnant women with type 1 diabetes – SHTG Adaptation
2020     Scottish Health Technologies Group (SHTG) Endobronchial valves for lung volume reduction in patients with severe or very severe emphysema - SHTG Recommendation
2024     Scottish Health Technologies Group (SHTG) Lung cancer AI
2024     Scottish Health Technologies Group (SHTG) Colon capsule endoscopy
2021     Scottish Health Technologies Group (SHTG) NHSScotland COPD Support Service: remote and self-management of high-risk patients with COPD using a web app and machine learning predictive modelling
2011     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of the ThinPrep imager® (HologicTM, Inc) for assisted cervical cytology compared with manual reading of liquid based cytology slides?
2011     Scottish Health Technologies Group (SHTG) The clinical and cost effectiveness of the use of brachytherapy to treat breast cancer
2011     Scottish Health Technologies Group (SHTG) What is the evidence base for the use of orthopaedic spinal surgery for mechanical low back pain or degenerative spondylolisthesis?
2026     Scottish Health Technologies Group (SHTG) Virtual wards
2011     Scottish Health Technologies Group (SHTG) The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer
2025     Scottish Health Technologies Group (SHTG) Intelligent Liver Function Testing (iLFT) for the earlier diagnosis of chronic liver disease (CLD)
2011     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults. This evidence note updates evidence note 33 published in March 2011
2025     Scottish Health Technologies Group (SHTG) Optune Gio® tumour-treating field therapy
2011     Scottish Health Technologies Group (SHTG) The clinical and cost effectiveness of long-term ventricular assist devices (VADs) as a bridge-to-transplant in adults
2011     Scottish Health Technologies Group (SHTG) Is radiofrequency ablation treatment a clinically and cost effective treatment to be offered to people with renal cancer in NHSScotland?
2012     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of human papillomavirus (HPV) testing, followed by liquid-based cytology triage of positive results, in primary screening for cervical cancer?
2012     Scottish Health Technologies Group (SHTG) High-risk human papillomavirus (HPV) testing as triage for women with mild or borderline cytology abnormalities
2012     Scottish Health Technologies Group (SHTG) Is radiofrequency ablation (RFA) treatment a suitable clinically and cost-effective treatment to be offered to patients with hepatocellular cancer in NHSScotland?
2012     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of microprocessor-controlled artificial knees compared with non-microprocessor-controlled alternatives?
2012     Scottish Health Technologies Group (SHTG) Radiofrequency ablation for Barrett's oesophagus with high grade dysplasia
2012     Scottish Health Technologies Group (SHTG) The use of functional electrical stimulation (FES) in adults with dropped foot. This evidence note updates evidence note 25 published in October 2008
2012     Scottish Health Technologies Group (SHTG) Safety and risk associated with free standing midwife led maternity units. This evidence note updates evidence note 18 published in August 2007
2013     Scottish Health Technologies Group (SHTG) Does the addition of positron emission tomography/computed tomography (PET/CT) to the routine investigation and assessment of patients with melanoma yield clinical and economic benefits?
2013     Scottish Health Technologies Group (SHTG) Open, laparoscopic and robot-assisted laparoscopic radical prostatectomy for localised prostate cancer.
2012     Scottish Health Technologies Group (SHTG) What implications does the organisation of vascular services have for rates of amputation?
2012     Scottish Health Technologies Group (SHTG) What is the published evidence of an association between hospital volume and outcome in elective carotid endarterectomy surgery?
2012     Scottish Health Technologies Group (SHTG) Is there a difference in operative mortality between endovascular aneurysm repair and open surgery in elective abdominal aortic aneurysm?
2012     Scottish Health Technologies Group (SHTG) What is the published evidence of an association between hospital volume and operative mortality for surgical repair (open and endovascular) of unruptured and ruptured abdominal aortic aneurysms?
2012     Scottish Health Technologies Group (SHTG) In patients with severe medically refractory gastroparesis (such as those requiring nutritional support), how effective and cost effective is gastric electrical stimulation (EnterraTM device) in reducing symptoms, reducing requirement for nutritional support or hospitalisation and improving quality of life, when compared with medical or alternative surgical management?
2012     Scottish Health Technologies Group (SHTG) What is the relative clinical effectiveness, cost effectiveness and safety of different bariatric surgery techniques (gastric bypass, gastric banding and sleeve gastrectomy)?
2012     Scottish Health Technologies Group (SHTG) In radiotherapy for cancer, what are the patient safety benefits and resource implications of the various in vivo methods of dosimetry to check received radiation dose, compared with pretreatment verification only?
2012     Scottish Health Technologies Group (SHTG) Is it clinically and cost effective to perform second-eye cataract surgery in the absence of other ocular co-morbidities in patients who have already had first-eye surgery?
2012     Scottish Health Technologies Group (SHTG) What is the impact of using thresholds (both for referral and surgery) for first-eye cataract surgery on the delivery of the cataract service and the resources associated with it?
2012     Scottish Health Technologies Group (SHTG) The clinical and cost-effectiveness of radiofrequency ablation for lung cancer
2012     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of temporal artery thermometers compared with infrared in-ear thermometers for temperature measurement in routine clinical practice?
2013     Scottish Health Technologies Group (SHTG) Are silver dressings clinically effective and cost effective for the healing of infected wounds and the prevention of wound infection relative to other types of dressing?
2013     Scottish Health Technologies Group (SHTG) Does the addition of positron emission tomography/computed tomography (PET/CT) to the routine investigation and assessment of patients with sarcoidosis yield clinical and economic benefits?
2013     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of dynamic elastomeric fabric orthoses (DEFOs) for cerebral palsy?
2013     Scottish Health Technologies Group (SHTG) Can wrist splints or steroid injections reduce the need for decompression surgery in carpal tunnel syndrome?
2013     Scottish Health Technologies Group (SHTG) What is the sensitivity and specificity of PET/CT compared with other diagnostic imaging modalities in determining the cause of pyrexia of unknown origin (PUO)? What is the clinical and cost effectiveness of PET/CT as a first-line investigation in patients with PUO?
2013     Scottish Health Technologies Group (SHTG) What is the clinical effectiveness, cost effectiveness and implications for safety of assessing anti-tumour necrosis factor (TNF)α drug levels and antibodies in children with moderate to severe inflammatory bowel disease compared with existing clinical strategies in use in NHS Scotland?
2013     Scottish Health Technologies Group (SHTG) PET/CT for the inversitgation of paraneoplastic syndromes (PNS)
2013     Scottish Health Technologies Group (SHTG) Is patient self-monitoring (including self-testing and self-management) of oral anticoagulation therapy safe, efficacious, and cost effective? (update of EN 27)
2014     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of treatment with renal denervation for patients with resistant hypertension?
2013     Scottish Health Technologies Group (SHTG) What is the evidence for the clinical and cost effectiveness of major trauma centres as the core component of a trauma service, compared with standard care for adults with major trauma?
2013     Scottish Health Technologies Group (SHTG) Is cone beam computed tomography (CBCT) clinically effective, cost-effective and safe compared with standard extraoral and intraoral radiography in the diagnosis of hard tissue pathology in routine dental practice?
2013     Scottish Health Technologies Group (SHTG) What approaches have been taken and efforts made to ensure public involvement in decision making relating to potential disinvestment in healthcare interventions and technologies?
2014     Scottish Health Technologies Group (SHTG) In the context of hypothyroidism, what is the evidence for the effectiveness of diagnostic tests and thyroid hormone replacement therapies?
2020     Scottish Health Technologies Group (SHTG) HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography
2026     Scottish Health Technologies Group (SHTG) Surface guided radiation therapy (SGRT)
2023     Scottish Health Technologies Group (SHTG) Technology enabled theatre scheduling tools
2026     Scottish Health Technologies Group (SHTG) Surface guided radiation therapy
2026     Scottish Health Technologies Group (SHTG) Surgical Care Practitioners
2024     Scottish Health Technologies Group (SHTG) Green theatres
2021     Scottish Health Technologies Group (SHTG) Elective surgery using mesh to repair primary or incisional hernias in adults
2021     Scottish Health Technologies Group (SHTG) A Unique Device Identifier (UDI) system for recording, identifying and recalling medical devices
2026     Scottish Health Technologies Group (SHTG) Wearable home-testing devices for diagnosing obstructive sleep apnoea syndrome (OSAHS)
2026     Scottish Health Technologies Group (SHTG) Out-of-hospital cardiac arrest (OHCA)
2026     Scottish Health Technologies Group (SHTG) Robotic assisted bronchoscopy (RAB)
2026     Scottish Health Technologies Group (SHTG) Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (OSAHS)
2026     Scottish Health Technologies Group (SHTG) Computed tomography fractional flow rate (CT-FFR)
2026     Scottish Health Technologies Group (SHTG) Specialist interventions for managing chronic non-malignant pain in adults
2025     Scottish Health Technologies Group (SHTG) Esaote® extremity MRI scanners
2026     Scottish Health Technologies Group (SHTG) Surgical care practitioners
2025     Scottish Health Technologies Group (SHTG) Home blood pressure monitoring for people with suspected or confirmed hypertension
2015     Scottish Health Technologies Group (SHTG) Magnetic resonance guided focused ultrasound surgery (MRgFUS) for the treatment of uterine fibroids
2025     Scottish Health Technologies Group (SHTG) Electrocardiogram (ECG) patch monitors for the detection of cardiac rhythm abnormalities
2025     Scottish Health Technologies Group (SHTG) Digital prevention programmes for people at risk of developing type 2 diabetes
2023     Scottish Health Technologies Group (SHTG) Priorities for the north imaging alliance
2023     Scottish Health Technologies Group (SHTG) The cost-effectiveness of the Scottish Hip Fracture Audit
2023     Scottish Health Technologies Group (SHTG) Capsule sponge technologies for the detection of Barrett’s oesophagus and early stage oesophageal cancer
2023     Scottish Health Technologies Group (SHTG) Technology-enabled theatre scheduling systems
2023     Scottish Health Technologies Group (SHTG) Digital prevention programme for people at risk of type 2 diabetes
2024     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Scottish Health Technologies Group (SHTG) Genotype testing to guide clopidogrel use after an ischaemic stroke or transient ischaemic attack (TIA)
2027     Scottish Health Technologies Group (SHTG) Specialist rehabilitation after major trauma
2026     Scottish Health Technologies Group (SHTG) Computed tomography coronary angiography (CTCA) and CT fractional flow reserve (CT-FFR) for investigation of patients with stable chest pain
2026     Scottish Health Technologies Group (SHTG) Pre-hospital extracorporeal cardiopulmonary resuscitation (ECPR) for adult patients experiencing refractory out-of-hospital cardiac arrest (OHCA)
2021     Scottish Medicines Consortium (SMC) Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021     Scottish Medicines Consortium (SMC) Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021     Scottish Medicines Consortium (SMC) Afamelanotide (Scenesse) for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP)
2021     Scottish Medicines Consortium (SMC) Upadacitinib for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
2021     Scottish Medicines Consortium (SMC) Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
2021     Scottish Medicines Consortium (SMC) Ozanimod for adult patients with relapsing remitting multiple sclerosis
2021     Scottish Medicines Consortium (SMC) Entrectinib as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; and who have not received a prior NTRK inhibitor; who have no satisfactory treatment options
2021     Scottish Medicines Consortium (SMC) Onasemnogene abeparvovec treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene
2021     Scottish Medicines Consortium (SMC) Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
2021     Scottish Medicines Consortium (SMC) Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
2021     Scottish Medicines Consortium (SMC) Melatonin (Slenyto) for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Safety and efficacy of reusable versus new balloon catheters for angioplasty]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Safety and efficacy of reusable versus new balloon catheters for angioplasty]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Nucleoplasty for treating disk herniation]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 13: The use of insulin glargine and insulin detemir to control type 1 diabetes mellitus]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 12: Clinical strategies for smoking cessation]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 11: Positron Emission Tomography (PET) in the diagnosis, staging and restaging of patients with colorectal cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 10: Rituximab in the treatment of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL)]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 09: Statins for the prevention of cardiovascular events]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 08: Drug-eluting stents and bare-metal stents in the treatment of coronary artery disease]